- Conditions
- Eosinophilia, Dyspepsia
- Interventions
- Not listed
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Kidney Disease (CKD)
- Interventions
- Vonsetamig
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 7 more
- Conditions
- Anemia, Leukemia, Neutropenia, Thrombocytopenia
- Interventions
- filgrastim, leridistim, cytarabine, daunorubicin hydrochloride
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 55 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Granulomatous Disease, Communicable Disease
- Interventions
- Gene Therapy Method for CGD, Isolex 300i Magnetic Cell Selector
- Drug · Device
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 5 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Leukemia
- Interventions
- Prophylactic White Cell Transfusion, Therapeutic White Cell Transfusion
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Myelodysplastic Syndromes, Neutropenia
- Interventions
- filgrastim, lintuzumab, cytarabine, etoposide, idarubicin
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2003
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Eosinophilic Gastritis, Eosinophilic Gastroenteritis
- Interventions
- AK002, Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Ventura, California + 18 more
- Conditions
- Breast Cancer, Neutropenia
- Interventions
- F-627, Neulasta
- Drug
- Lead sponsor
- EVIVE Biotechnology
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hematologic Malignancies
- Interventions
- Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Shwachman-Diamond Syndrome, Shwachman-Diamond Syndrome-Like
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Timeline
- 2016 – 2090
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Boston, Massachusetts • Cincinnati, Ohio
- Conditions
- Infection, Neutropenia
- Interventions
- Not listed
- Lead sponsor
- Karius, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Eosinophilic Esophagitis
- Interventions
- APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
- Drug · Procedure
- Lead sponsor
- Ellodi Pharmaceuticals, LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 59
- States / cities
- Dothan, Alabama • Mobile, Alabama • Scottsdale, Arizona + 54 more
- Conditions
- Primary Immunodeficiency, Common Variable Hypogammaglobulinemia, X-linked Hypogammaglobulinemia, Hypogammaglobulinemia, Immunodeficiency With Hyper-IgM, Wiskott-Aldrich Syndrome
- Interventions
- Gammaplex (Intravenous immunoglobulin)
- Biological
- Lead sponsor
- Bio Products Laboratory
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 7
- States / cities
- North Palm Beach, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- IRL201104, Placebo
- Drug
- Lead sponsor
- Revolo Biotherapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Murrieta, California • Centennial, Colorado + 19 more
- Conditions
- Immune System Diseases, Eosinophilia, Helminthiasis, Hypersensitivity, Parasitic Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Year to 100 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Absorbable sugars
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Neutropenia, Sarcoma
- Interventions
- voriconazole
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 11 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 7
- States / cities
- Orange, California • San Diego, California • Bethesda, Maryland + 4 more
- Conditions
- Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
- Interventions
- Dexpramipexole Dihydrochloride, Placebo
- Drug
- Lead sponsor
- Areteia Therapeutics
- Industry
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 1,061 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 89
- States / cities
- Bakersfield, California • La Palma, California • Newport Beach, California + 73 more
- Conditions
- Chronic Granulomatous Disease
- Interventions
- Sirolimus, Donor peripheral blood stem cells., Cyclophosphamide post transplant, Total body 200cGy, Cyclophosphamide, Fludarabine, Busulfan
- Drug · Biological · Radiation
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- PTLD, Lymphoid Tumor, Hematopoietic/Lymphoid Cancer, Plasmacytic Hyperplasia PTLD, Infectious Mononucleosis, Florid Follicular Hyperplasia PTLD, Polymorphic PTLD, Monomorphic PTLD, Classical Hodgkin Lymphoma Type PTLD
- Interventions
- Rituximab, Brentuximab Vedotin, Bendamustine
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Rochester, Minnesota
- Conditions
- HIV Infections, Cytopenias
- Interventions
- Filgrastim
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more
- Conditions
- Diabetes
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Gastroesophageal Reflux Disease (GERD), Eosinophilic Esophagitis (EoE), Functional Dyspepsia
- Interventions
- Standard of Care esophagogastroduodenoscopy (EGD) with measurement of mucosal impedance
- Diagnostic Test
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Eosinophilic Gastritis, Eosinophilic Duodenitis
- Interventions
- lirentelimab (AK002), Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 54 more